Post-doctoral training/certification:
- PGY-2 Cardiology Pharmacy Residency - Loma Linda University Medical Center & School of Pharmacy, 2020
- PGY-1 Pharmacy Practice Residency - Loma Linda University Medical Center & School of Pharmacy, 2019
- Board Certified Pharmacotherapy Specialist (BCPS), 2019
- Post-graduate teaching certificate - Loma Linda University School of Pharmacy, 2019
Doctor of Pharmacy:
- University of Rhode Island College of Pharmacy (6-year PharmD), 2018
During Dr. Ryu's post-doctoral training at Loma Linda University Medical Center & School of Pharmacy, she was actively involved with teaching in and facilitation of the cardiology I and II courses, as well as the pharmacy practice course. She also precepted multiple students on their internal medicine and cardiology rotations for their Introductory Pharmacy Practice Experiences and Advanced Pharmacy Practice Experiences.
Dr. Ryu's research interests include heart failure/transplant, cardio-oncology, antithrombotics, and chronic cardiovascular disease states (e.g. hypertension, hyperlipidemia).
- California Society of Health-System Pharmacists (CSHP)
- American Society of Health-System Pharmacists (ASHP)
- American College of Cardiology Cardiovascular Team Section: Pharmacists Committee
Dr. Ryu stays committed to state/national pharmacy organizations and serves on an advisory board for an overseas pharmacy school. Additionally, she was previously on the executive board of directors for Western States Conference (WSC)--the primary regional conference for pharmacy residents on the west coast.
Ryu R.DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban). Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221144044.
Ryu R, Hauschild C, Bahjri K, Tran H. The Usage of Concomitant Beta-Blockers with Vasopressors and Inotropes in Cardiogenic Shock. Med Sci (Basel). 2022;10:64
Ryu R,Tran R. DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions. Clin Appl Thromb Hemost. 2022;28:10760296221103578.
Shurrab M, Ryu R, Jackevicius CA. Off-Label Direct Oral Anticoagulant Dosing: Caution Advised. Circulation: Cardiovascular Quality and Outcomes. 2021;14:e008608.
Nandkeolyar S, Doctorian T, Fraser G, Ryu R, et al. Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support. Clinical Medicine Insights: Cardiology. 2021.https://doi:10.1177/11795468211049449
Vu, A, Qu, TT, Ryu, R, et al. Critical Analysis of Apixaban Dose Adjustment Criteria. Clinical and Applied Thrombosis/Hemostasis. 2021;27:1-6. https://doi.org/10.1177/10760296211021158
Ryu, R. Letter to the editor: Response to "Thromboembolic events in atrial fibrillation: Different level of risk and pattern between peripheral artery disease and coronary artery disease,” by Yu-Sheng Lin, et al., 2021. Archives of Cardiovascular Diseases. 2021;114:176-186. https://doi.org/10.1016/j.acvd.2021.05.002
Ryu, R. Update on the Safety and Efficacy of Oral Anticoagulation in CKD and ESRD. U.S. Pharmacist. 2021;45(3)36-40.
Ryu, R, Tran HT, Bahjri K. Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic. Metabolic Syndrome and Related Disorders. 2020;19(2):1-4. doi: 10.1089/met.2020.0100
Nandkeolyar S, Doctorian T, Fraser G, Ryu, R, Kagabo W, Fearon C, et al. Predictors of in-patient mortality in patients on short-term low-dose inotropes for cardiogenic shock. Journal of American College of Cardiology. 2020;75(11):769.
Ryu R, Ward KE. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): current status and future prospects. Front. Oncol. 2018;8:277. doi: 10.3389/fonc.2018.00277
Chavez M, Chavez P, Rogala B, Ryu R. Supportive and Palliative Care for Cancer. In Hume AL, Orr KK (Eds.). Principles and Practice of Botanicals as an Integrative Therapy. Boca Raton: Taylor & Francis Group, 2019. Print.
Sravankumar A, Sadighi A, Ryu R, Akhlaghi F. Contribution of Cytochrome P450 and other enzymes to the metabolism of FDA approved drugs between 2005-2016. Drug Metabolism and Pharmacokinetics, 2017;S12:2.
Ryu R, Hume AL. Polypharmacy. In: Ferri FF (Ed.). Ferri’s Clinical Advisor 2019. Elsevier, Elsevier, United States, 2018. Print.
Charpentier MM, Rogala B, Ryu R, Patterson B. Botanical Use in Cancer Prevention and Treatment. In: Hume AL, Orr KK (Eds.). Principles and Practice of Botanicals as an Integrative Therapy. Boca Raton: Taylor & Francis Group, 2019. Print.
Sravankumar A, Sadighi A, Ryu R, Akhlaghi F. Physicochemical Properties, Biotransformation and Transport Pathways of Old and New Medications: A Systematic Review of Top 200 Most Prescribed Drugs versus FDA Approved Drugs Between 2005 to 2016. Clin Pharmacokinet. 2019. Review. Funded by the National Institutes of Health (grant #R15-GM101599)